Bone Marrow Transplantation
RSSArticles
-
Systemic Radiation Therapy Using Receptor Specific Radioligands: Experience with
-
Cancer Screening's Next Chapter: Mobile CT Scanning for Lung Cancer
-
Lessons in Supportive Care, IX: Do Medical Care Interventions Ever Save Money?
-
Strategy to Overcome Rituximab Resistance in Patients with Indolent Lymphoma
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles). -
Second-line Docetaxel Improves Survival and Symptom Control in Advanced Esophagogastric Cancer
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone. -
Bendamustine-Bortezomib-Dexamethasone for Relapsed Myeloma
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone. -
Toward More Effective Neoadjuvant Breast Cancer Therapy
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response. -
Cancer-reducing Effect of OCPs in BRCA1/BRCA2 Carriers: Do They Work?
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population. -
Redefining the Natural History of Borderline Ovarian Tumors
This paper represents the largest collection of cases with central path review and provides better clarity to prognostic factors previously intimated from retrospective work. -
Pancreatic Cancer Patients Live Longer when nab-Paclitaxel Is Added to Gemcitabine
It is indeed ironic that 16 years after the landmark Burris study, innovations in pancreatic cancer treatment still lack essential quality-of-life data.